Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

Blood - 14 Jul 2016

Lampson Benjamin L, Kasar Siddha N, Matos Tiago R, Morgan Elizabeth A, Rassenti Laura, Davids Matthew S, Fisher David C, Freedman Arnold S, Jacobson Caron A, Armand Philippe, Abramson Jeremy S, Arnason Jon E, Kipps Thomas J, Fein Joshua, Fernandes Stacey, Hanna John, Ritz Jerome, Kim Haesook T, Brown Jennifer R

Abstract excerpt

Idelalisib is a small-molecule inhibitor of PI3Kδ with demonstrated efficacy for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). To evaluate idelalisib as front-line therapy, we enrolled 24 subjects in a phase 2 study consisting of 2 months of idelalisib monotherapy followed by 6 months of combination therapy with idelalisib and the anti-CD20 antibody ofatumumab. After a median follow-up...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemical and Drug Induced Liver Injury

Share to Hepatitis, Autoimmune

Share to Immunoglobulin Heavy Chains

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Purines

Share to Quinazolinones

Source

Open in PubMed Open full text

Identifiers

PMID: 27247136
DOI: 10.1182/blood-2016-03-707133
PMCID: PMC4946200

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.PMID 27247136Read ↗

Functional testing of PI3K inhibitors stratifies responders to idelalisib and identifies treatment vulnerabilities in idelalisib-refractory/intolerant chronic lymphocytic leukemiaSemantic proximity Read ↗

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.Semantic proximity Read ↗

Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors.Semantic proximity Read ↗

Hepatic Failure Associated with Immune Checkpoint Inhibitors: A Real-world Study from the Food and Drug Administration Adverse Event Reporting System (FAERS) DatabaseSemantic proximity Read ↗

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune liver diseaseSemantic proximity Read ↗

The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell FunctionSemantic proximity Read ↗

Clinical and Liver Biochemistry Phenotypes, and Outcome in 133 Patients with Anti-seizure Drug-Induced Liver Injury.Semantic proximity Read ↗

Remdesivir and the Liver: A Concise Narrative Review of Remdesivir-Associated Hepatotoxicity in Patients Hospitalized Due to COVID-19Semantic proximity Read ↗

Idelalisib — A PI3Kδ Inhibitor for B-Cell CancersSemantic proximity Read ↗

Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE studySemantic proximity Read ↗

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.Semantic proximity Read ↗

Phenotyping Hepatic Immune-Related Adverse Events in the Setting of Immune Checkpoint Inhibitor Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.